Monoclonal Antibodies: Progress is Slow but Sure

Publisher Website
Google Scholar
Abstract
The article by Carrasquillo and colleagues in this issue1 is one step along the path taking the production of monoclonal antibodies from a laboratory tour de force to a usable diagnostic or therapeutic clinical tool. Despite the small number of patients in their study, these investigators have generated important new data concerning the behavior of a Radio-labeled monoclonal antibody, [111In]T101, in patients with cutaneous T-cell lymphoma, a rather rare disease. In addition to showing which metastases are most likely to be detected (lymph-node and thick erythrodermatous skin lesions) or missed (liver and spleen deposits and skin plaques) in imaging . . .